Chlorprothixen 15 Lechiva

Psychoses, including schizophrenia, depressive states during menopause, states of arousal associated with fear and tension, dyscirculatory encephalopathy, traumatic brain injuries, alcoholic delirium, sleep disorders in anxiety states, psychosomatic, neurotic disorders in children, in patients with burns, dermatoses with persistent itching.

Inside, during or after a meal, without chewing, with water. The dosage regimen is determined individually. Usually adults: 30-50 mg 3-4 times a day. Treatment begins with low doses, then the dose is gradually increased until the signs of the disease disappear. Most of the dose is usually given at night. The daily dose for adults should not exceed 600 mg.

For children: 15-30 mg 3-4 times a day.

Absolute values: hypersensitivity, poisoning with drugs that depress the central nervous system (including alcohol), comatose states of any etiology.

Relative values: epilepsy, parkinsonism, a tendency to collapse, severe violations of the function of the kidneys, liver, heart and respiration, angle-closure glaucoma, myasthenia gravis, pregnancy, lactation (you should stop breastfeeding), old age.

Extrapyramidal disorders, increased fatigue, headache, dry mouth, orthostatic hypertension, tachycardia, accommodation disorders, visual impairment, constipation, urination disorders, jaundice, amenorrhea, galactorrhea, gynecomastia, libido changes, carbohydrate metabolism disorders, increased appetite, weight gain, agranulocytosis, leukopenia, photosensitization, photodermatitis, withdrawal syndrome (with sudden cessation treatment).

• Neuroleptics

Increases the effect of drugs that depress the central nervous system, including alcohol.

In a dry place, at a temperature of 10-25 °C.

Keep out of reach of children.

Do not use after the expiration date indicated on the package.

1 tablet, coated, contains chlorprotixen 15 or 50 mg, in a blister of 10 pcs., in a box of 3 blisters.

N05AF03 Chlorprothixene

• F20 Schizophrenia
• F29 Inorganic psychosis, unspecified
• F41 Other anxiety disorders
• F91 Behavioral disorders
• G47. 0 Sleep disorders and sleep maintenance [insomnia]
• L20 Atopic dermatitis
• L29 Itching
• N95. 1 Menopausal and menopausal conditions in women
• R45. 1 Anxiety and agitation
• R45. 6 Physical aggressiveness
• R45. 7 State of emotional shock and stress, unspecified
• T90. 5 Consequences of intracranial trauma